The purpose of the study is to test the effect of Sitagliptin on the healing of stable, nonhealing diabetic foot...
Vanda Pharmaceuticals Inc. announced the results from its Phase III study of tradipitant in motion sickness, confirming the previously reported results demonstrating that tradipitant is effective in the prevention of vomiting associated with motion sickness
HOPE study demonstrates that local inflammation is a suitable target for treatment in patients with debilitating disease1
A new comparative effectiveness analysis, published online in Wound Repair & Regeneration, reported that Apligraf, from Novartis, has demonstrated improved...
Dicobalt Edetate Injection is a specific antidote for acute cyanide poisoning. In view of the difficulty of certain diagnosis in emergency situations, it is recommended that Dicobalt Edetate Injection only be given when the patient is tending to lose or has lost consciousness. The product should not be used as a precautionary measure.
Osteoarthritis (OA) most commonly affects knee joints, and the next most commonly affected sites are the hands and hips.
Topline results were reported from the U.S. Phase III 596 patient HANDEL study of Toctino(alitretinoin) from Basilea Pharma in severe...
GSK informed Basilea that it has elected to discontinue its U.S. alitretinoin (Toctino) program. Global rights to Toctino (alitretinoin) were...
Merz North America has announced that Radiesse has received FDA approval for hand augmentation to correct volume loss in the...
Takeda Pharmaceutical announced new real-world data evaluating the comparative effectiveness of Entyvio (vedolizumab) and tumor necrosis factor-alpha (TNFalpha)-antagonist therapy in...